Skip to content
Doug Maready, MD
TreatmentsFor patients & the public

← All topics

Pharmacotherapy & Pipeline

GLP-1 Medications & Hair Loss

Why hair shedding shows up on semaglutide and tirzepatide, what the data actually show, and how to handle it — without derailing a therapy that's working.

DM
Reviewed by Doug Maready, MD
A plain-language guide to what the research shows
By the numbers
5.3%
of people who lost >20% of their body weight reported hair loss — vs 2.5% of those who lost less. It tracks how much and how fast you lose weight, not the medication itself.
Wegovy (semaglutide) product monograph, Novo Nordisk, 2024
Core Concepts

Six things to know about this hair loss.

Tap any card for a clear, plain-language summary of what's known.

01

Telogen Effluvium 101

The medical name for the temporary, reversible shedding behind almost all GLP-1 hair loss. Your follicles aren't being destroyed.

Read pearls
02

Why It Happens

It's driven by fast, significant weight loss and the nutrition gaps that come with it — not the drug attacking your hair.

Read pearls
03

What the Studies Show

In the big clinical trials it was uncommon, usually mild, and more often reported by women.

Read pearls
04

What Real Life Shows

Outside the studies, it gets reported a bit more often — especially by women who lose weight quickly.

Read pearls
05

The Regrowth Surprise

For some people, these medications have actually improved hair. Follicles carry GLP-1 receptors — so the effect can go either way.

Read pearls
06

What You Can Do

Knowing it's temporary — and what supports regrowth — makes the wait a lot easier.

Read pearls
For Clinicians

Two clinical workflows.

For healthcare professionals — these open detailed walkthroughs with step-by-step reasoning.

Evaluation & Workup

The patient says their hair is falling out. Confirm the pattern, time the onset, order the right labs, and know the red flags. Click each step to expand.

Open walkthrough

Management & Prevention

Nutrition, micronutrients, titration, minoxidil, and time — compared, with when (and when not) to stop the GLP-1.

Open walkthrough